InFlectis BioScience SAS is a Nantes, France–based biopharmaceutical company that discovers and develops drugs to treat protein misfolding diseases. It is led by Philippe Guédat, President and CEO. Its lead candidate is IFB-088, which the company plans to demonstrate for clinical effectiveness in humans and then partner with a pharmaceutical organization for further development and commercialization. In parallel, InFlectis is developing new chemical series for non-orphan diseases whose etiology involves accumulation of misfolded proteins and plans to select a second candidate, a selective inhibitor of PPP1R15A. The Medical Research Council (MRC) in the UK is a historical shareholder and co‑owns patents protecting the use of IFB-088 for several neurodegenerative diseases, including CMT. The company completed a €6M Series A financing and intends to use the funds to accelerate regulatory preclinical development and to finance the first clinical study in healthy volunteers.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2016